This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cleveland BioLabs Loses Out On Defense Contract

A Defense Department rejection left Cleveland BioLabs (CBLI - Get Report) stock in the dust on Friday.

Shares plummeted nearly 60% after the Buffalo, N.Y., company's proposed treatment for the gastrointestinal effects of radiation sickness, Protectan CBLB502, wasn't chosen for a lucrative DoD contract award.

Protectan, which has yet to undergo clinical human testing, is the company's lead candidate for acute radiation syndrome. Had it been selected by the DoD, the compound's development would have gotten funding through approval at the Food and Drug Administration, according to the company's latest quarterly filing.

The DoD instead chose Maryland-based Osiris Therapeutics (OSIR - Get Report), granting it a $224.7 million package to develop an adult stem-cell therapy called Prochymal jointly with Genzyme (GENZ).

"We are deeply disappointed by this unexpected decision," said Cleveland CEO Michael Fonstein in a press release, particularly given what Fonstein described as "aggressive" and detailed prior feedback on the proposal from the DoD.

Still, Cleveland vows to continue developing the drug, aiming for regulatory approval by 2009, and it intends on responding to any future DoD solicitations.

Chief Scientific Officer Andrei Gudkov also said the company plans on continuing talks with the Department of Health and Human Services and other friendly governments "who are interested in its potential to protect against terrorist threats and nuclear disaster."

Cleveland shares ended down $4.69, or 58.6%, at $3.31. Osiris jumped $1.29, or 10.3%, to $13.86, and Genzyme dipped 0.5% to $75.05.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CBLI $4.03 -0.25%
OSIR $10.28 -1.72%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs